161581-95-9Relevant articles and documents
INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER
-
Paragraph 00197, (2014/01/17)
Disclosed herein are methods and compositions related to the discovery that cholesterol inhibitors induce the anti-proliferative protein, estrogen receptor beta (ERβ), in both ERα- positive and ERα-negative breast cancer cell lines, including triple negat
Oxidosqualene cyclase (OSC) inhibitors for the treatment of dyslipidemia
Dehmlow, Henrietta,Ackermann, Jean,Aebi, Johannes,Blum-Kaelin, Denise,Chucholowski, Alexander,Coassolo, Philippe,Hartman, Peter,Kansy, Manfred,Maerki, Hans Peter,Morand, Olivier,Von Der Mark, Elisabeth,Panday, Narendra,Ruf, Armin,Thoma, Ralf,Schulz-Gasch, Tanja
, p. 72 - 76 (2007/10/03)
Novel inhibitors of oxidosqualene cyclase (OSC) for the treatment of dyslipidemia are reported. Starting point for the chemistry program was a set of compounds derived from a fungicide project which, in addition to high affinity for OSC from Candida albicans, also showed high affinity for the human enzyme (hOSC). Here the evaluation process of different scaffolds is outlined for two representative series, the phenyl substituted benzo[d]isothiazoles and the aminocyclohexanes. The most promising compounds derived from the latter series were further profiled in vivo and showed promising properties with respect to modulation of lipid parameters. Schweizerische Chemische Gesellschaft.
Amino alkenyloxybenzene derivatives
-
, (2008/06/13)
A method of lowering cholesterol which comprises administering to a host requiring such treatment an effective amount of a compound of the formula STR1 wherein one of R1 and R2 is C1-7 -alkyl and the other is C1-7 -alkyl or C2-6 -alkenyl-methyl; L is C1-11 -alkylene or C2-11 -alkenylene optionally bonded to the phenyl group via an O atom or L is 1,4-phenylene; n is 0 or, when L contains an O atom, n is 0 or 1; Q is C1-7 -alkyl, C2-10 -alkenyl or a group of formula STR2 wherein R is H, halogen, CF3, CN or NO2 ; R3 and R4 are H, C1-4 -alkyl or halogen; and R5 is H or, when R is H, R5 is H or halogen; or a pharmaceutically acceptable acid addition salt thereof, as well as certain compounds of formula I, are described.